(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Barry Manilow to have surgery for early-stage lung cancer and postpones January concerts - 2NASA's Artemis 2 pilot Victor Glover listens to 'Whitey on the Moon' every Monday. This is why.
- 3Scientists sent a menstrual cup to space. This is how it went
- 4Scientists are getting our robotic explorers ready to help send humans to Mars
- 5The Best 15 Applications for Efficiency and Association
- the 6 Shrewd Beds for seniors: A Complete Survey
- Space station changes command, setting stage for Crew 11 departure
- Step by step instructions to Buy a Jeep Wrangler on a Senior's Spending plan
- Dominating the Art of Composing: Creator Bits of knowledge
- Airbnb Unveils Airport Pickup Service Across 125 Cities in Global Expansion
- Share your pick for the tree that you love for its novel magnificence!
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- Is relief in sight? Flu season still brutal but cases are declining.
- SpaceX launches Starlink satellites on its 150th Falcon 9 mission of the year
